Tallac Therapeutics develops antibody-drug conjugates (ADCs) that utilize Toll-like Receptor Agonist Antibody Conjugates (TRAAC) to deliver TLR9 agonists directly to tumors, enhancing immune activation within the tumor microenvironment. Their approach addresses the challenge of ineffective immune responses in cancer treatment by enabling precise and systemic delivery of oligonucleotide-based therapies.
Funding
$77M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
HTFounders
Product
Problem
Many cancer treatments struggle with ineffective immune responses within the tumor microenvironment, limiting their ability to fight the disease. Traditional approaches often fail to deliver immune-stimulating agents directly to the tumor, resulting in systemic toxicity and limited efficacy. This challenge hinders the development of effective immunotherapies for a wide range of cancers.
Solution
Tallac Therapeutics develops Toll-like Receptor Agonist Antibody Conjugates (TRAACs), a novel class of antibody-drug conjugates (ADCs) designed to enhance immune activation specifically within the tumor microenvironment. TRAACs precisely deliver a potent Toll-like receptor 9 (TLR9) agonist (T-CpG) directly to tumors, stimulating both innate and adaptive immune responses. This targeted approach aims to overcome the limitations of systemic delivery, reducing off-target effects and maximizing anti-tumor activity. By harnessing the power of next-generation ADCs, Tallac seeks to develop more effective cancer immunotherapies. Several TRAAC molecules are currently in discovery and development, with two programs already in clinical trials.
Target Audience
The primary target audience includes patients with advanced solid tumors who may benefit from enhanced immune activation within the tumor microenvironment, as well as oncologists and researchers seeking more effective cancer immunotherapies.
Features
- Utilizes Toll-like Receptor Agonist Antibody Conjugates (TRAAC) technology for targeted delivery of TLR9 agonists.
- Employs a potent TLR9 agonist (T-CpG) to trigger immune activation within the tumor microenvironment.
- Enables precise conjugation of therapeutic oligo payloads, including CpG oligonucleotides, antisense oligonucleotides, and siRNA.
- Designed for systemic administration with the goal of minimizing off-target effects.
- Two TRAAC programs are currently in clinical development.